Entact Bio

aid: entactbio
name: Entact Bio
description: 'Entact Bio is a preclinical-stage biotechnology company based in Watertown, Massachusetts, developing a new
  class of small-molecule precision medicines called Enhancement-Targeting Chimeric (ENTAC) molecules. Where targeted protein
  degradation removes disease-causing proteins, Entact Bio works in the opposite direction: its ENTAC molecules recruit deubiquitinases
  (DUBs) to strip ubiquitin chains from beneficial proteins in order to extend their half-life, relocate them, or otherwise
  restore their function. The company''s proprietary Encompass platform combines biological, chemical, and computational tools
  to identify disease targets amenable to protein enhancement across oncology, autoimmune disease, and rare genetic disorders.
  Entact Bio launched in December 2022 with an $81 million Series A co-led by Qiming Venture Partners USA and venBio Partners,
  with participation from Abingworth, Brandon Capital, and others. It is a therapeutics research organization and publishes
  no public developer program, API, or machine-readable API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/entactbio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Targeted Protein Degradation
- Preclinical
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/entactbio-domain-security.yml
- type: Website
  url: https://entactbio.com/
- type: About
  url: https://entactbio.com/science/
- type: Team
  url: https://entactbio.com/team/
- type: News
  url: https://entactbio.com/news-publications/
- type: Careers
  url: https://entactbio.com/careers/
- type: Contact
  url: https://entactbio.com/contact-us/
- type: LinkedIn
  url: https://www.linkedin.com/company/entact-bio
- type: Crunchbase
  url: https://www.crunchbase.com/organization/entact-bio
- type: LLMsTxt
  url: llms/entactbio-llms.txt
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: blocked
  reason: bot-challenge
  detail: 'entactbio.com is fronted by a SiteGround bot-protection edge that answers every path — including the site root
    and /robots.txt — with HTTP 202, an `sg-captcha: challenge` header and a 180-byte meta-refresh shell pointing at /.well-known/sgcaptcha/,
    so not one page, spec path or /.well-known/ document could be read from the provider''s own host under any user agent;
    DNS separately shows no api./docs./developer./portal. host to retry against, and the company is a preclinical therapeutics
    business with no evident developer program.'
  evidence:
  - url: https://entactbio.com/
    status: 202
  - url: https://entactbio.com/robots.txt
    status: 202
  - url: https://entactbio.com/llms.txt
    status: 202
  - url: https://entactbio.com/openapi.json
    status: 202
  - url: https://entactbio.com/.well-known/agent-card.json
    status: 202
  - url: https://entactbio.com/.well-known/security.txt
    status: 202
  - url: https://api.github.com/orgs/EntactBio
    status: 200
  checked: '2026-08-12'